Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cocktail of cancer drugs targets Hard-to-Treat head and neck tumors

NCT ID NCT06912087

Recruiting now Disease control Sponsor: University of Chicago Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial is testing a new three-drug combination for people with head and neck cancer that has come back or spread. The drugs include a targeted therapy (zanzalintinib), an immunotherapy (pembrolizumab), and another targeted antibody (cetuximab). The main goal is to find the safest dose and see if the combination can shrink tumors or slow the disease. About 36 adults with incurable, recurrent or metastatic squamous cell carcinoma of the head and neck will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

zanzalintinib (a targeted therapy drug) combined with pembrolizumab (an immunotherapy) and cetuximab (a targeted antibody)

What this could lead to

If this combination proves safe and effective, it could offer a new treatment option for people with advanced head and neck cancer that has returned or spread.

What could go wrong

This is an early Phase I trial with only 36 participants, focused on safety and dosing. The combination may cause significant side effects, and it is too early to know if it will improve survival or tumor control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASM METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck neoplasm Head and Neck Neoplasms head and neck squamous cell carcinoma metastatic neoplasm metastatic squamous cell carcinoma Neoplasm Metastasis Neoplasm Recurrence, Local squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, SQUAMOUS CELL HEAD AND NECK NEOPLASMS METASTATIC SQUAMOUS CELL CARCINOMA NEOPLASM METASTASIS NEOPLASM RECURRENCE, LOCAL RECURRENT SQUAMOUS CELL CARCINOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Chicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••